⚕ GalenOps CRO console
← SITE006 (GBR)

SITE006-0059

completed
Study: A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer Phase III · Site: SITE006 (GBR) (Dr. Rossi) · consented 2022-04-28
Adverse events
9
Serious AEs
1
Open data queries
0
Luna dropout signal
–

Adverse events

severe serious assessed 2026-08-18

Grade 4 Adrenal insufficiency — outcome: RECOVERED/RESOLVED; onset 2022-07-01 (study day 47); relationship: not assessed; serious criteria: life-threatening

mild assessed 2026-08-18

Grade 1 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-07-14 (study day 60); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-07-26 (study day 72); relationship: N

mild assessed 2026-08-18

Grade 1 Constipation — outcome: RECOVERED/RESOLVED; onset 2022-08-21 (study day 98); relationship: N

severe assessed 2026-08-18

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-27 (study day 135); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-10-16 (study day 154); relationship: not assessed

moderate assessed 2026-08-18

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-11-04 (study day 173); relationship: Y

severe assessed 2026-08-18

Grade 3 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2022-12-12 (study day 211); relationship: not assessed

severe assessed 2026-08-18

Grade 3 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2022-12-28 (study day 227); relationship: Y

Data queries

No data queries.

☾ Luna engagement

This participant doesn't use Luna.